title: Octacosanol enhances the proliferation and migration of human umbilical vein endothelial cells via activation of the PI3K/Akt and MAPK/Erk pathways.
abstract: Atherosclerosis is characterized by endothelial dysfunction, lipid deposition, fibro-proliferative reactions and inflammation. Octacosanol is a high-molecular-weight primary aliphatic alcohol. As the main component of a cholesterol-lowering drug, octacosanol could inhibit lipids accumulation and cholesterol metabolism. To explore the indication of octacosanol on endothelial protection, we evaluated its effects on the proliferation and migration of human umbilical vein endothelial cells (HUVEC). Cell viability assay using methyl thiazolyl tetrazolium and 5-ethynyl-2'-deoxyuridine revealed that 3.125 μg/ml octacosanol promoted the proliferation of HUVEC. A cell migration assay indicated that 0.781 and 3.125 μg/ml octacosanol increased the migration of HUVEC. Moreover, the phosphorylation levels of Akt and Erk1/2 were significantly elevated under exposure to octacosanol. Blocking the activation of Akt and Erk with their potent inhibitors LY294002 and PD98059, respectively, markedly attenuated the octacosanol-induced proliferation and migration of HUVEC. These findings demonstrated for the first time that octacosanol enhanced the proliferation and migration of HUVEC and mediated these effects through activation of the PI3K/Akt and MAPK/Erk1/2 signaling pathways.
authors: Department of Geriatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, People's Republic of China.
authors: Yu-Wei
authors: YW
authors: Liu
authors: Pei-Yuan
authors: PY
authors: Zuo
authors: Xiang-Nan
authors: XN
authors: Zha
authors: Xing-Lin
authors: XL
authors: Chen
authors: Rong
authors: R
authors: Zhang
authors: Xiao-Xiao
authors: XX
authors: He
authors: Cheng-Yun
authors: CY
authors: Liu
mesh_terms: D000924:Anticholesteremic Agents / Q000494:pharmacology*; D002465:Cell Movement / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects*; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D005233:Fatty Alcohols / Q000494:pharmacology*; D061307:Human Umbilical Vein Endothelial Cells / Q000166:cytology* / Q000187:drug effects; D006801:Humans; D020929:Mitogen-Activated Protein Kinase Kinases / Q000378:metabolism; D051058:Oncogene Protein v-akt / Q000378:metabolism; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D015398:Signal Transduction
chemical_list: D000924:Anticholesteremic Agents; D005233:Fatty Alcohols; C044309:1-octacosanol; D019869:Phosphatidylinositol 3-Kinases; D051058:Oncogene Protein v-akt; D048049:Extracellular Signal-Regulated MAP Kinases; D020929:Mitogen-Activated Protein Kinase Kinases
references: Lipids. 2008 Feb;43(2):109-15
references: 18004604
references: Int J Biol Sci. 2013 Nov 09;9(10):1057-69
references: 24250251
references: Cell Tissue Res. 2012 Aug;349(2):433-46
references: 22592627
references: Circ J. 2013;77(3):772-9
references: 23171663
references: Eur J Pharmacol. 2008 Jul 7;588(2-3):141-50
references: 18513715
references: Acta Clin Belg. 2006 Sep-Oct;61(5):213-9
references: 17240734
references: J Biol Chem. 1998 Nov 13;273(46):30336-43
references: 9804796
references: Cell Mol Life Sci. 2004 Sep;61(17):2224-43
references: 15338053
references: Vascul Pharmacol. 2014 May-Jun;61(2-3):63-71
references: 24751361
references: JACC Cardiovasc Interv. 2011 Oct;4(10):1057-66
references: 22017929
references: Am Heart J. 2002 Feb;143(2):356-65
references: 11835043
references: Neurol Res. 2011 Jul;33(6):614-24
references: 21708071
references: Nat Med. 2002 Nov;8(11):1211-7
references: 12411947
references: Exp Cell Res. 2005 Apr 1;304(2):417-31
references: 15748888
references: Cell. 2001 Feb 23;104(4):503-16
references: 11239408
references: J Biol Chem. 2000 Apr 14;275(15):10761-6
references: 10753867
references: J Pharm Pharmacol. 1995 Sep;47(9):731-3
references: 8583384
references: Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1579-84
references: 21205894
references: PLoS One. 2013 Oct 24;8(10):e78764
references: 24205314
references: J Neurosci. 2002 Feb 1;22(3):644-53
references: 11826094
references: Pharmacology. 2001 Jan;62(1):29-35
references: 11150920
references: Mol Med Rep. 2015 Feb;11(2):1504-8
references: 25373458
references: J Oleo Sci. 2010;59(8):451-5
references: 20625237
references: Int J Mol Med. 2014 Jul;34(1):299-306
references: 24789534
references: Br J Pharmacol. 2012 Feb;165(3):591-602
references: 21557734
references: J Cell Physiol. 1988 May;135(2):317-23
references: 2453524
references: Circ Res. 2002 Jun 28;90(12):1243-50
references: 12089061
references: J Pharm Pharmacol. 1997 Oct;49(10):999-1002
references: 9364410
references: Blood. 2005 Mar 1;105(5):1970-6
references: 15507525
references: Nutr Rev. 2003 Nov;61(11):376-83
references: 14677572
references: Biomater Sci. 2014 Apr 1;2(4):548-559
references: 24653833
references: J Neurosci Res. 2014 Nov;92 (11):1520-8
references: 24939171
references: Nature. 2011 May 19;473(7347):298-307
references: 21593862
references: Br J Nutr. 1995 Mar;73(3):433-41
references: 7766566
references: Nature. 1993 Apr 29;362(6423):801-9
references: 8479518
references: JAMA. 1984 Jan 20;251(3):351-64
references: 6361299
references: Anc Sci Life. 2012 Apr;31(4):151-9
references: 23661861
references: J Pharmacol Sci. 2014;126(3):198-207
references: 25341684
references: Lipids. 2009 Oct;44(10):907-16
references: 19763655
references: Cell J. 2014 Summer;16(2):203-10
references: 24567937
references: Biochem Pharmacol. 2014 Jul 15;90(2):135-44
references: 24821109
references: Exp Neurol. 2001 Aug;170(2):297-304
references: 11476596